1016 studies found for:    Open Studies | "Antineoplastic Agents, Alkylating"
Show Display Options
Rank Status Study
1 Recruiting Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Conditions: Leukemia, Chronic Myeloid;   Myelodysplastic Syndromes;   Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Interventions: Procedure: Unrelated allogeneic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide;   Drug: Thymoglobulin
2 Recruiting Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy;   Drug: Chemotherapy (control)
3 Recruiting Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer
Conditions: Recurrent Epithelial Ovarian Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Peritoneal Cancer
Interventions: Biological: DPX-Survivac;   Drug: Cyclophosphamide;   Drug: Epacadostat (INCB024360)
4 Not yet recruiting Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Leukemia
Interventions: Drug: Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);   Drug: Cytarabine(Actavis Italy S.p.A);   Drug: Fludarabine (Bayer);   Drug: granulocyte colony-stimulating factor (KirinKunpeng);   Drug: rabbit ATG(Sanofi/Genzyme)
5 Recruiting Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor
Condition: Intracranial Non-germinomatous Germ Cell Tumor
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Bleomycin;   Drug: Thiotepa;   Drug: Melphalan;   Radiation: Reduced dose radiotherapy
6 Recruiting Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma
Condition: Unresectable Localized Soft Tissue Sarcoma
Interventions: Drug: Cisplatin;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Carboplatin;   Radiation: Radiotherapy;   Drug: Thiotepa;   Drug: Melphalan
7 Recruiting Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma
Condition: Intracranial Germinoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Bleomycin;   Radiation: Reduced dose of radiotherapy
8 Not yet recruiting Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
Condition: Acute Myeloid Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Procedure: Graft cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Procedure: CIML NK cell infusion;   Drug: ALT-803;   Procedure: Leukapheresis
9 Not yet recruiting Temozolomide Chronotherapy for High Grade Glioma
Conditions: Glioma;   Glioblastoma Multiforme
Interventions: Drug: Temozolomide;   Other: Functional Assessment of Cancer Therapy - Brain;   Other: Wrist actimetry device
10 Not yet recruiting A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: PNK-007;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Human recombinant Interleukin-2 (rhIL-2)
11 Not yet recruiting Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Selinexor;   Drug: Melphalan;   Drug: Dexamethasone;   Procedure: Autologous Hematopoietic Cell Transplantation (HCT)
12 Recruiting Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM
Condition: Glioblastoma Multiforme
Intervention: Drug: Metformin
13 Recruiting HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
Condition: Sickle Cell Disease
Intervention: Drug: Fludarabine monophosphate
14 Not yet recruiting Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
Conditions: Adult Solid Neoplasm;   Childhood Solid Neoplasm;   Metastatic Neoplasm
Interventions: Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL;   Biological: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine;   Procedure: Positron Emission Tomography
15 Not yet recruiting Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1
Conditions: HLA-A2 Positive Cells Present;   Metastatic Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
Interventions: Biological: Aldesleukin;   Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis
16 Recruiting Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Drug: Prednisone
17 Not yet recruiting A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
Condition: Diffuse Large B Cell Lymphoma
Interventions: Drug: SCT400 plus CHOP;   Drug: Rituximab plus CHOP
18 Recruiting Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer
Condition: Extensive-stage Small Cell Lung Cancer
Interventions: Drug: Temozolomide;   Drug: first-line chemotherapy;   Radiation: Prophylactic cranial irradiation;   Radiation: thoracic radiotherapy
19 Recruiting Response-based Treatment of High-risk Neuroblastoma
Condition: Newly Diagnosed High Risk Neuroblastoma
Interventions: Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Carboplatin;   Procedure: Tandem HDCT/auto-SCT;   Radiation: Radiotherapy;   Drug: Interleukin-2;   Drug: Isotretinoin;   Radiation: MIBG
20 Not yet recruiting A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
Condition: Glioblastoma
Interventions: Drug: Temozolomide;   Drug: Aprepitant;   Drug: Minocycline;   Drug: Disulfiram;   Drug: Celecoxib;   Drug: Sertraline;   Drug: Captopril;   Drug: Itraconazole;   Drug: Ritonavir;   Drug: Auranofin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years